NCT01565200 2025-03-31
ZEPHIR
Jules Bordet Institute
Phase 2 Completed
Clinical Trials
6 trialsNCT02023996 2024-12-10
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT04757090 2021-12-23
89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Washington University School of Medicine
Phase 2 Withdrawn
NCT02286843 2021-06-18
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01832051 2015-11-05
Clinical Value of 89Zr-trastuzumab PET
University Medical Center Groningen
Phase 2 Completed
NCT01081600 2013-05-14
AUY922
University Medical Center Groningen
Completed